Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
Authors
Keywords
-
Journal
CARDIOVASCULAR RESEARCH
Volume 112, Issue 1, Pages 429-442
Publisher
Oxford University Press (OUP)
Online
2016-08-06
DOI
10.1093/cvr/cvw194
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
- (2016) Michel Farnier et al. ATHEROSCLEROSIS
- Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature
- (2016) Michalina Kołodziejczak et al. ATHEROSCLEROSIS
- Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
- (2016) Hagai Tavori et al. CARDIOVASCULAR RESEARCH
- Blood Brain Barrier Disruption in Diabetic Stroke Related to Unfavorable Outcome
- (2016) Xinfeng Yu et al. CEREBROVASCULAR DISEASES
- Imbalanced cholesterol metabolism in Alzheimer's disease
- (2016) Zhao Xue-shan et al. CLINICA CHIMICA ACTA
- Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis
- (2016) John H. Boyd et al. Journal of Innate Immunity
- Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
- (2015) Zufeng Ding et al. ANTIOXIDANTS & REDOX SIGNALING
- PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverSignificance
- (2015) Annie Demers et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary PreventionSignificance
- (2015) Yiming M. Zhu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension
- (2015) Jean-Mathieu Berger et al. ATHEROSCLEROSIS
- Effects of lipoprotein apheresis on PCSK9 levels
- (2015) U. Julius et al. ATHEROSCLEROSIS SUPPLEMENTS
- The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis
- (2015) Amélie Bonnefond et al. DIABETOLOGIA
- ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
- (2015) John J.P. Kastelein et al. EUROPEAN HEART JOURNAL
- The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
- (2015) Michael J. Lipinski et al. EUROPEAN HEART JOURNAL
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
- (2015) Christopher P. Cannon et al. EUROPEAN HEART JOURNAL
- Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events
- (2015) Paul M. Ridker et al. EUROPEAN HEART JOURNAL
- The Cellular and Molecular Basis of Translational Immunometabolism
- (2015) Giuseppe Danilo Norata et al. IMMUNITY
- Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9
- (2015) Quoc-Tuan Le et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
- (2015) Rocco Romagnuolo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line
- (2015) Massimiliano Ruscica et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Removal of Plasma Mature and Furin-Cleaved Proprotein Convertase Subtilisin/Kexin 9 by Low-Density Lipoprotein-Apheresis in Familial Hypercholesterolemia: Development and Application of a New Assay for PCSK9
- (2015) Mika Hori et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
- (2015) Harold Bays et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk
- (2015) Yascara G. Luna Saavedra et al. Journal of Clinical Lipidology
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
- (2015) Patrick M. Moriarty et al. Journal of Clinical Lipidology
- Local effects of human PCSK9 on the atherosclerotic lesion
- (2015) Ilaria Giunzioni et al. JOURNAL OF PATHOLOGY
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease
- (2015) Jian-Jun Li et al. MEDICINE
- Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure
- (2015) Elzbieta Sucajtys-Szulc et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder?
- (2015) Jay P. Patel et al. NEURAL PLASTICITY
- Elevated Circulating PCSK-9 Concentration in Renal Failure Patients is Corrected by Renal Replacement Therapy
- (2014) Marcin Konarzewski et al. AMERICAN JOURNAL OF NEPHROLOGY
- Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease
- (2014) Sha Li et al. ATHEROSCLEROSIS
- Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels
- (2014) H. Abujrad et al. ATHEROSCLEROSIS
- HDL in innate and adaptive immunity
- (2014) A. L. Catapano et al. CARDIOVASCULAR RESEARCH
- Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms
- (2014) Shirya Rashid et al. CIRCULATION
- Clearance of Plasma Proprotein Convertase Subtilisin/Kexin 9 by Low-Density Lipoprotein Apheresis
- (2014) P.B. Duell et al. CIRCULATION RESEARCH
- Plasma proprotein convertase subtilisin–kexin type 9 is predominantly related to intermediate density lipoproteins
- (2014) Arjan J. Kwakernaak et al. CLINICAL BIOCHEMISTRY
- PCSK9 and LDLR degradation
- (2014) Thomas A. Lagace CURRENT OPINION IN LIPIDOLOGY
- Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study
- (2014) Giovanni Corrao et al. DIABETES CARE
- Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia
- (2014) Jennifer G. Robinson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Isolation and characterization of the circulating truncated form of PCSK9
- (2014) Bomie Han et al. JOURNAL OF LIPID RESEARCH
- Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
- (2014) Susan Kühnast et al. JOURNAL OF LIPID RESEARCH
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
- (2014) Erik Stroes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 is Present in Human Cerebrospinal Fluid and is Maintained at Remarkably Constant Concentrations Throughout the Course of the Day
- (2014) Yan Q. Chen et al. LIPIDS
- Apoptosis in Alzheimer’s Disease: An Understanding of the Physiology, Pathology and Therapeutic Avenues
- (2014) M. Obulesu et al. NEUROCHEMICAL RESEARCH
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bridging Lipid Metabolism and Innate Host Defense
- (2014) C. dos Santos et al. Science Translational Medicine
- PCSK9 is a critical regulator of the innate immune response and septic shock outcome
- (2014) K. R. Walley et al. Science Translational Medicine
- Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment
- (2014) Christian Werner et al. VASCULAR PHARMACOLOGY
- PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
- (2014) Giuseppe Danilo Norata et al. VASCULAR PHARMACOLOGY
- Plasma PCSK9 in Nephrotic Syndrome and in Peritoneal Dialysis: A Cross-sectional Study
- (2013) Kyubok Jin et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Hepatic Cholesterol Homeostasis
- (2013) Allan D. Sniderman et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Beyond LDL-C lowering: Distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency
- (2013) Minna T. Jänis et al. ATHEROSCLEROSIS
- PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
- (2013) Emile Levy et al. ATHEROSCLEROSIS
- Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation
- (2013) K. L. Ma et al. CARDIOVASCULAR RESEARCH
- Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor
- (2013) Hagai Tavori et al. CIRCULATION
- Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis
- (2013) Hagai Tavori et al. CIRCULATION RESEARCH
- Risk factors for atherosclerosis in patients with chronic kidney disease: recognition and management
- (2013) Sudarshan Balla et al. CURRENT OPINION IN PHARMACOLOGY
- New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
- (2013) Giuseppe Danilo Norata et al. EUROPEAN HEART JOURNAL
- Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
- (2013) Tanja Kosenko et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease
- (2013) A. Baragetti et al. JOURNAL OF INTERNAL MEDICINE
- Hepatitis C Virus Stimulates Low-Density Lipoprotein Receptor Expression To Facilitate Viral Propagation
- (2013) G. H. Syed et al. JOURNAL OF VIROLOGY
- Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
- (2013) Bertrand Cariou et al. Nutrition & Metabolism
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
- (2013) Maryssa Canuel et al. PLoS One
- ApoER2 and VLDLr Are Required for Mediating Reelin Signalling Pathway for Normal Migration and Positioning of Mesencephalic Dopaminergic Neurons
- (2013) Ahmed Sharaf et al. PLoS One
- Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy
- (2013) Frederick Raal et al. Journal of the American Heart Association
- Blood-Brain Barrier Disruption after Cardiac Surgery
- (2012) J.G. Merino et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor
- (2012) Hua Sun et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Apolipoprotein B Secretory Regulation by Degradation
- (2012) Sven-Olof Olofsson et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment
- (2012) Arjan J. Kwakernaak et al. ATHEROSCLEROSIS
- PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
- (2012) Kai Kysenius et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
- (2012) Vikas Sharotri et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
- (2012) Michael T. Lipari et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population
- (2012) Iris Postmus et al. JOURNAL OF LIPID RESEARCH
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
- (2012) Paul M Ridker et al. LANCET
- Crosstalk between reverse cholesterol transport and innate immunity
- (2012) Kathleen M. Azzam et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
- (2011) Anna Roubtsova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
- (2011) Nicola Ferri et al. ATHEROSCLEROSIS
- Emerging role of high density lipoproteins as a player in the immune system
- (2011) Giuseppe Danilo Norata et al. ATHEROSCLEROSIS
- Oxidative stress and inflammation: Implications in uremia and hemodialysis
- (2011) Carmelo Libetta et al. CLINICAL BIOCHEMISTRY
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
- (2011) M. John Chapman et al. EUROPEAN HEART JOURNAL
- Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
- (2011) Anna Albecka et al. HEPATOLOGY
- PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke
- (2011) Estelle Rousselet et al. JOURNAL OF LIPID RESEARCH
- PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax–caspase9–caspase3 pathway
- (2011) Chun-Yan Wu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure–function relation to therapeutic inhibition
- (2011) G. Tibolla et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Blood–Brain Barrier Breakdown in Acute and Chronic Cerebrovascular Disease
- (2011) Yi Yang et al. STROKE
- Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people
- (2011) Shelby Sullivan et al. Translational Research
- Trypanosoma cruzi Utilizes the Host Low Density Lipoprotein Receptor in Invasion
- (2011) Fnu Nagajyothi et al. PLoS Neglected Tropical Diseases
- In VivoEvidence That Furin from Hepatocytes Inactivates PCSK9
- (2010) Rachid Essalmani et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
- (2010) Mali Liu et al. JOURNAL OF LIPID RESEARCH
- PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
- (2009) Bertrand Cariou et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
- (2009) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Triglyceride-Rich Lipoproteins and Plasma Lipid Transport
- (2009) Richard J. Havel ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion
- (2009) Cédric Langhi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents
- (2009) A. Baass et al. CLINICAL CHEMISTRY
- Cholesterol metabolism and pancreatic β-cell function
- (2009) Michelle Fryirs et al. CURRENT OPINION IN LIPIDOLOGY
- Hepatic nuclear factor 1-α: inflammation, genetics, and atherosclerosis
- (2009) Angela D Armendariz et al. CURRENT OPINION IN LIPIDOLOGY
- Cell biology, regulation and inhibition of β-secretase (BACE-1)
- (2009) Clare E. Hunt et al. FEBS Journal
- PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
- (2009) Majambu Mbikay et al. FEBS LETTERS
- PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression
- (2009) Patrick Labonté et al. HEPATOLOGY
- Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation
- (2009) Steve Poirier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity†
- (2008) Daping Fan et al. BIOCHEMISTRY
- PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1
- (2008) Mary Cabell Jonas et al. EMBO REPORTS
- The activation and physiological functions of the proprotein convertases
- (2008) N SEIDAH et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Regulation of ApoB Secretion by the Low Density Lipoprotein Receptor Requires Exit from the Endoplasmic Reticulum and Interaction with ApoE or ApoB
- (2008) Daniel A. Blasiole et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
- (2008) Janice Mayne et al. Lipids in Health and Disease
- Blood-brain barrier tight junction permeability and ischemic stroke
- (2008) Karin E. Sandoval et al. NEUROBIOLOGY OF DISEASE
- APCSK9Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction
- (2008) Sekar Kathiresan NEW ENGLAND JOURNAL OF MEDICINE
- Influence of low-density lipoprotein (LDL) receptor on lipid composition, inflammation and parasitism during Toxoplasma gondii infection
- (2007) Luciane R. Portugal et al. MICROBES AND INFECTION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now